Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
M&A activity
confidence 95%
filed 2026-08-10
Item 7.01
ConnectM announced completion of a previously disclosed Share Swap Agreement with Blue Cloud Softech Solutions Limited, closing on June 17, 2026, whereby ConnectM transferred 100% of Global Impex Inc. (its India-based operations) to Blue Cloud in exchange for 160 million newly issued Blue Cloud shares representing approximately 17.33% of Blue Cloud's post-issue equity. This is a material disposition of a significant operating asset (94.11% ownership interest in Global Impex) structured as a non-cash share-for-shares exchange, constituting a material acquisition/disposition event under Item 1.01 or 1.02 of Form 8-K.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-10
EX-99.1
This exhibit announces a strategic collaboration agreement between Instinct Bio and PT PARVA CANDELA to develop a cosmetics business in Indonesia. The disclosure describes a material operational and strategic partnership involving joint market development, manufacturing, distribution, and revenue-sharing arrangements (50% profit share plus ingredient supply, royalties, and licensing fees). While the collaboration does not constitute a traditional M&A transaction or acquisition, it represents a significant strategic business initiative that would affect a reasonable investor's assessment of the company's growth strategy and market expansion plans, particularly as the company explicitly identifies it as "the third component of the Company's organic growth strategy."
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
Plug Power Inc. issued a press release on August 10, 2026 disclosing second quarter 2026 financial results, including revenue of ~$178 million, gross margin improvement to breakeven, net cash usage of ~$61 million, and raised full-year 2026 revenue guidance to 15-16% growth. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes key financial metrics, operational highlights, and forward guidance material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a straightforward earnings release disclosing Q2 2026 financial results for Tactile Systems Technology, Inc. The Item 2.02 filing explicitly states the company "issued a press release disclosing our results of operations and financial condition for our most recently completed fiscal quarter," with the press release attached as Exhibit 99.1. The exhibit contains detailed quarterly and six-month financial results including revenue ($85.7M, up 9% YoY), net income ($7.8M vs $3.2M prior year), and updated 2026 guidance, making this a material disclosure affecting investor assessment of the registrant's financial performance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-08-10
Item 1.01
Varex Imaging entered into a definitive Agreement and Plan of Merger with Teledyne Technologies on August 10, 2026, providing for the acquisition of Varex at $18.90 per share in cash, with an aggregate transaction value of approximately $1.1 billion. The transaction was unanimously approved by both boards, requires stockholder approval and regulatory clearances, and is expected to close in early 2027.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-08-10
Item 5.02
In connection with the Merger Agreement, equity awards (Company Options, RSUs, and PSUs) held by four Named Executives (Sanyal, Maheshwari, Hartmann, and Jonaitis) will be accelerated and vested, with aggregate cash payouts totaling approximately $14.4 million.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-10
Item 8.01
Alumis disclosed topline results from the ONWARD3 Phase 3 long-term extension study for envudeucitinib, showing 54% PASI 100 skin clearance and a favorable safety profile, with plans to submit an NDA to the FDA in Q4 2026. This is a material clinical milestone for a late-stage biopharmaceutical company's lead candidate, affecting investor assessment of regulatory and commercialization prospects, but does not fit the earnings_release category (which typically applies to financial results) or other specific event types. The disclosure centers on clinical trial progress and regulatory pathway advancement rather than financial results, M&A activity, or governance matters.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-10
Item 1.01
Skyworks Solutions issued $2.0 billion in aggregate principal amount of senior notes across three series (2028, 2032, and 2036) on August 10, 2026, with net proceeds intended to finance approximately $3.0 billion in cash consideration for the Qorvo acquisition. The notes are senior unsecured obligations with stated interest rates and maturity dates.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
Simon Property Group issued a press release on August 10, 2026 disclosing second quarter 2026 earnings results for the period ended June 30, 2026, including Real Estate FFO per share of $3.29 (up 7.9% year-over-year) and increased full-year 2026 guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
TELA Bio issued a press release on August 10, 2026 announcing financial results for Q2 2026 ended June 30, 2026, with consolidated statements of operations and balance sheets attached as Exhibit 99.1. The disclosure includes revenue of $19.3 million (down 4% YoY), net loss of $11.3 million, and cash position of $30.4 million, along with withdrawal of full-year 2026 guidance. This is a standard quarterly earnings release material to investors assessing the company's financial performance and cash runway.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a clear earnings release disclosing American Public Education's financial results for Q2 2026 (three and six months ended June 30, 2026). The filing explicitly states "On August 10, 2026, American Public Education, Inc. (the 'Company') issued a press release reporting financial results for the three and six months ended June 30, 2026" and includes consolidated statements of income, segment information, and forward guidance. The press release highlights key metrics including consolidated revenue of $171.7 million (5.5% YoY increase), net income of $9.8 million, and adjusted EBITDA of $20.7 million (36.8% increase), along with raised full-year 2026 guidance.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-10
The 6-K discloses completion of a PIPE (private investment in public equity) on August 10, 2026, in which LightInTheBox issued 21,397,409 ordinary shares at $0.2566667 per share for approximately $5.49 million in gross proceeds. The shares were issued in reliance on Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D—classic exemptions for unregistered equity issuances. This is a material dilutive equity offering that would affect a reasonable investor's assessment of ownership and capital structure.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-08-10
Item 5.03
On August 10, 2026, the Board of Directors adopted a Section 382 Tax Asset Preservation Plan (Rights Agreement) with Computershare Trust Company, N.A., as rights agent, designed to protect net operating losses and tax attributes by deterring acquisitions of 4.9% or more of outstanding common stock. The plan includes amendment of the Articles of Incorporation to designate Series C Cumulative Preferred Stock and materially affects shareholder rights and the company's capital structure through August 10, 2029.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-10
EX-99.1
Agomab Therapeutics announced the proposed appointments of Marino Garcia and Dr. Naimish Patel as non-executive members of the Board of Directors, to be submitted for shareholder approval at a Special General Meeting on September 11, 2026. Both candidates bring significant industry experience in biotechnology leadership and clinical development, directly relevant to the company's strategic direction.
View raw filing on EDGAR →
8-K
Earnings release
confidence 94%
filed 2026-08-10
Item 2.02
Amplify Energy issued a press release reporting financial and operating results for Q2 2026, disclosing net income of $17.3 million, Adjusted EBITDA of $8.6 million, production of 6.8 MBopd, and forward guidance.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-08-10
Item 8.01
The Board approved a share repurchase program authorizing up to $15.0 million in common stock repurchases through December 31, 2026, representing approximately 10% of outstanding shares.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
Riot Platforms disclosed Q2 2026 financial results with total revenue of $174.2 million (14% YoY increase), including $113.7 million in bitcoin mining revenue, $37.3 million in engineering revenue, and $23.2 million in data center revenue.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-10
Item 8.01
Riot Platforms executed a 20-year, 191 MW data center lease with a leading frontier AI lab expected to generate approximately $9.1 billion in total contract revenue, establishing the company as a leading AI data center developer.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
TTEC issued a press release on August 10, 2026 announcing second quarter 2026 financial results for the period ended June 30, 2026. The disclosure includes detailed GAAP and Non-GAAP revenue, operating income, EBITDA, earnings per share, and cash flow metrics, along with revised full-year 2026 guidance. This is a standard quarterly earnings release filed under Item 2.02 and attached as Exhibit 99.1, which is the primary purpose of this 8-K filing.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
Energy Services of America issued a press release on August 10, 2026, disclosing its results of operations and financial condition for the three and nine months ended June 30, 2026. The filing reports quarterly financial results including revenue of $130.0 million (25.5% YoY increase), net income of $3.3 million ($0.18 per diluted share), and a 33% increase in quarterly dividend. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and capital allocation decisions.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
AECOM disclosed its third quarter fiscal 2026 financial results via press release on August 10, 2026, as required under Item 2.02. The filing includes quarterly revenue ($3.6 billion), operating loss ($76 million GAAP), net loss ($84 million), and diluted EPS ($-0.65), along with updated full-year guidance reflecting a $337 million pre-tax charge on a Construction Management project. This is a standard quarterly earnings release with material financial impacts warranting investor disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
This is a clear earnings release disclosing Hallador's second quarter 2026 financial and operating results. The filing explicitly states "On August 10, 2026, Hallador Energy Company issued a press release announcing its second quarter 2026 financial and operating results," with the press release attached as Exhibit 99.1. The exhibit contains detailed financial summaries including revenue ($101.5M), net loss ($15.2M), and adjusted EBITDA ($2.9M loss), along with operational highlights and forward guidance. This is material to investors as it reflects the company's quarterly earnings performance and strategic project updates.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a quarterly earnings release for Q2 2026 disclosing financial and operating results for the period ended June 30, 2026. The press release (Exhibit 99.1) provides comprehensive financial highlights including pounds drummed, shipped, and sold; product sales revenue of $14.4 million; cash position of $95.3 million; and cash cost per pound metrics. The filing is made under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases, and includes a conference call announcement for discussion of quarterly results.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-10
EX-99.1
Biophytis announces regulatory approval from Brazil's ANVISA to conduct the Phase 2 OBA clinical trial for obesity, a material operational and clinical milestone. The disclosure describes approval of a multi-regional clinical development program, partnership arrangements with Blanver and EMBRAPII, and the company's strategic expansion into a second indication (obesity) alongside its primary indication (sarcopenia). This is a significant clinical and operational development that would affect a reasonable investor's assessment of the company's pipeline progress and market opportunity, but does not fit the specific event categories of earnings release, M&A activity, or other named types.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
WhiteHorse Finance issued a press release on August 10, 2026 announcing its financial results for the second quarter ended June 30, 2026, including net investment income of $4.681 million ($0.217 per share), net asset value per share of $11.77, portfolio fair value of $569.2 million, and a declared quarterly distribution of $0.25 per share.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure announces financial results including revenue of $32.9 million (down 2%), net income of $4.0 million or $0.25 per diluted share (down from $5.2 million or $0.32 in Q2 2025), and detailed segment performance. The press release is furnished as Exhibit 99.1 and includes management commentary on operational performance and forward guidance, which is typical of earnings releases material to investors.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-08-10
Item 5.02
The filing discloses approval by the Compensation and Talent Development Committee of a new executive short-term incentive bonus plan effective October 1, 2026, which supersedes and replaces multiple prior bonus plans. This is a compensatory arrangement for directors and officers (all Section 16 executive officers are designated as Participants), involving material changes to incentive structure and bonus eligibility criteria. The disclosure is characteristic of Item 5.02(e) executive compensation disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-10
Item 2.02
Coronado Global Resources disclosed its H1 2026 financial results on August 10-11, 2026, reporting revenue of US$981 million, a net loss of US$418 million, and an adjusted EBITDA loss of US$83 million, along with operational highlights and forward guidance for 2026.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-08-10
EX-99.1
Fortuna Mining Corp. announced the acquisition of the 190 km² Bambadji advanced gold exploration project in Senegal from Barrick Mining Corporation and IAMGOLD Corporation for US$200 million in cash, with definitive transaction agreements dated August 10, 2026. This is a material acquisition of mineral exploration assets that consolidates prospective strike along a Tier-1 gold corridor and is immediately adjacent to Fortuna's feasibility-stage Diamba Sud Gold Project, representing a significant strategic expansion of the company's exploration portfolio.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-08-10
Item 1.01
Cherry Hill Mortgage Investment Corporation entered into a definitive Agreement and Plan of Merger with TPG Mortgage Investment Trust on August 9, 2026, whereby CHMI will merge into MITT's subsidiary. The transaction is valued at $117.5 million (29% premium to CHMI's closing price), with CHMI shareholders receiving 0.3063 shares of MITT common stock and $0.93 in cash per share, and is expected to close in Q4 2026 subject to stockholder approval.
View raw filing on EDGAR →
8-K
Earnings release
confidence 75%
filed 2026-08-10
Item 2.02
The Item 2.02 disclosure reports Cherry Hill's second quarter 2026 financial results, including GAAP net income of $1.3 million ($0.04 per share), earnings available for distribution of $5.5 million ($0.15 per diluted share), and book value of $3.16 per share. While the press release also announces a merger agreement with TPG Mortgage Investment Trust, the Item 2.02 section itself is focused on quarterly results disclosure, which is the primary earnings release event. The merger is a separate material event but is not the focus of Item 2.02 specifically.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
Item 2.02 discloses Motorcar Parts of America's fiscal 2027 first quarter earnings results for the period ended June 30, 2026, with a press release furnished as Exhibit 99.1. The filing reports net sales of $168.0 million, a net loss of $13.4 million ($0.71 per share), and includes consolidated financial statements, balance sheet data, and management commentary on results and full-year guidance reaffirmation. This is a standard quarterly earnings release material to investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-10
Item 1.01
Prairie Operating Co. entered into a letter agreement with Hudson Bay PH XIX LLC that amends warrant issuance terms, including extension of the Anniversary Warrant Issuance Date and a contingent issuance of a Second Penny Warrant to purchase 3,000,000 shares at $0.01 per share, representing dilutive equity instruments that could substantially increase share count.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-08-10
Item 8.01
Tyson Foods announced a debt tender offer to purchase up to $1.2 billion in aggregate principal amount of outstanding senior notes across three series (3.550% due 2027, 5.400% due 2029, and 4.350% due 2029). While technically a repurchase of existing debt rather than issuance of new debt, the filing explicitly conditions the tender offer on the company's "contemporaneous offering of one or more series of notes" (the Financing Condition) to raise proceeds sufficient to fund the repurchase. This represents a material refinancing activity involving the creation of new direct financial obligations to retire existing debt.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
Lincoln Educational Services issued a press release on August 10, 2026, announcing Q2 2026 financial results with revenue of $142.6 million (up 22.4%) and Adjusted EBITDA of $12.7 million (up 42.4%), while reiterating full-year 2026 financial guidance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-08-10
Item 2.01
Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences, creating a fully integrated global biosimilars leader and extending the company's growth profile into the 2030s with access to a $300+ billion global biologics market. The transaction was funded through $350 million in incremental financing under Amendment No. 4 to the Term Loan Credit Agreement, and Kashiv shareholders received 28,942,098 shares of Amneal Class A Common Stock as consideration.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a standard earnings release disclosing Q2 2026 financial results for Nu Skin Enterprises. The Item 2.02 filing announces revenue of $320.1 million (down 17.1% YoY), EPS of $(5.14) (or $0.20 adjusted), and provides Q3 and full-year 2026 guidance. The press release includes detailed consolidated financial statements, segment revenue breakdowns, and customer metrics, which are typical components of a quarterly earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
This is a classic Item 2.02 earnings release disclosing Rocket Pharmaceuticals' second quarter 2026 financial results for the period ended June 30, 2026. The filing includes detailed financial metrics (R&D expenses of $29.5M, G&A expenses of $17.4M, net income of $123.2M, cash position of $283.7M, and cash runway guidance into Q2 2028), along with operational highlights including FDA approval of KRESLADI, a $180M Priority Review Voucher sale, and clinical progress updates. The press release is furnished as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-10
Item 3.02
Tilray issued 1,377,334 shares of common stock in unregistered private debt-for-equity exchange transactions, exchanging equity for $6 million principal of convertible notes. This is a dilutive issuance of unregistered equity securities under Item 3.02, relying on Section 3(a)(9) exemption. The transaction materially increases share count and would affect investor assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-10
Item 1.01
Tyson Foods entered into an underwriting agreement on August 10, 2026 to issue $1 billion in aggregate principal amount of senior notes ($500 million 5.100% notes due 2031 and $500 million 5.600% notes due 2037), with proceeds intended for a debt tender offer and general corporate purposes.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-10
EX-99.1
This is a press release announcing Alcon's second-quarter 2026 financial results, including net sales of $2.8 billion (up 8% reported, 7% constant currency), core diluted EPS of $0.84 (up 11%), and updated full-year 2026 guidance with raised core operating margin and core diluted EPS growth expectations. The document explicitly states "reported its financial results for the three and six month periods ending June 30, 2026" and includes detailed segment performance, cash flow metrics, and forward guidance—all hallmarks of a quarterly earnings release.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-10
EX-99.1
This press release announces FDA approval of an Investigational New Drug (IND) application for Lucid-MS, enabling Quantum BioPharma to advance into Phase 2 clinical trials for progressive multiple sclerosis. While this is a significant regulatory milestone and clinical development advancement, it does not fit the discrete event categories of earnings_release, exec_appointment/departure, M&A activity, or other named material events. The disclosure is clearly operational and strategic in nature—a major clinical/regulatory milestone that would materially affect investor assessment of the company's pipeline progress and competitive positioning in the multi-billion-dollar MS market. The company explicitly characterizes this as "a breakthrough moment" and "transformative moment," and the CEO emphasizes it as "an important strategic milestone." This is material to a reasonable investor evaluating the company's development trajectory and market opportunity.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-08-10
EX-99.1
This is a press release announcing Standard Lithium's "Second Quarter 2026 Results" for the three and six-month periods ended June 30, 2026. The document discloses financial metrics (cash of $137.3 million, working capital of $137.1 million, no debt as of June 30, 2026) and operational highlights, and explicitly states "This news release should be read in conjunction with the Company's Consolidated Financial Statements and MD&A." While the release emphasizes operational milestones (NEPA approval, construction contracts, demonstration plant achievements), the primary purpose is to report quarterly financial and operating results, making it an earnings release. The material operational progress on the SWA Project (FID pathway, major regulatory clearance) reinforces materiality to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
PennantPark Investment Corporation issued a press release on August 10, 2026, announcing financial results for the third quarter ended June 30, 2026. The disclosure includes detailed operating results (net investment income of $8.9 million, net realized gains of $12.0 million), portfolio metrics (total assets of $1,193.2 million, net asset value per share of $6.56), and distributions declared per share. This is a standard quarterly earnings release furnished under Item 2.02, which is material to investors assessing the company's financial performance and dividend sustainability.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
PennantPark Floating Rate Capital Ltd. issued a press release on August 10, 2026 announcing its financial results for the third fiscal quarter ended June 30, 2026. The disclosure includes comprehensive quarterly financial highlights (net assets, NAV per share, investment income, net investment income per share, distributions declared), portfolio activity, and detailed results of operations. This is a standard quarterly earnings release furnished under Item 2.02, with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-10
EX-99.1
Allied Gold announces the closing of a non-brokered private placement of 12,800,000 common shares to Zijin Gold at C$32.55 per share for aggregate gross proceeds of C$416,640,000. This is a material dilutive equity issuance that results in Zijin Gold holding approximately 9.2% of the company's outstanding shares. The transaction is a classic private placement that would materially affect a reasonable investor's assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-10
Item 7.01
Silexion disclosed an updated corporate presentation on August 10, 2026, containing an updated timeline for clinical testing and regulatory approval of its lead product candidate SIL 204. The presentation details the Phase 2/3 clinical trial initiated in July 2026, with specific milestones including Segment 1 completion expected Q2 2027, Segment 2 initiation Q3 2027, and Segment 3 initiation Q3 2030. This is a material operational/strategic disclosure regarding the company's clinical development program timeline and manufacturing collaborations with Catalent and Axolabs, which would affect a reasonable investor's assessment of the registrant's product development progress and commercialization pathway.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-10
EX-99.1
This is a press release announcing monday.com's second quarter 2026 financial results, including revenue of $364.6 million (22% YoY growth), GAAP and non-GAAP operating metrics, net income per share, and forward guidance for Q3 and full-year 2026. The exhibit contains condensed consolidated financial statements and detailed business metrics (ARR, net dollar retention, customer counts). This is a classic earnings release disclosing quarterly financial results, material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-10
EX-99.1
This is a press release announcing Perion Network's second quarter 2026 financial results, including revenue of $98.2 million, net loss of $6.8 million (GAAP), and adjusted EBITDA of $2.8 million. The document explicitly states "Perion Reports Second Quarter 2026 Results" and includes consolidated statements of operations, balance sheets, and cash flows for the periods ended June 30, 2026. The company also narrowed its full-year 2026 guidance, which is material to investors assessing the registrant's financial trajectory.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-10
This is a press release announcing Camtek's Q2 2026 financial results, including record revenues of $133.2 million, GAAP net income of $23.3 million, and forward guidance for Q3 and H2-26. The release includes detailed financial statements (balance sheet, income statement, and GAAP-to-non-GAAP reconciliation) and management commentary on business performance and outlook. This is a discrete earnings announcement, not a periodic financial report filing.
View raw filing on EDGAR →